A previous study reported that intraperitoneal injection of AMF exerts body weight-lowering effects and protection against HFD-induced metabolic dysfunction by reducing fasting glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and TG levels in HFD-fed rats. The gene discussed is INS; the disease is Insulin resistance.